Main Session
Sep
28
CT 01 - Clinical Trials
3 - 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial
Presenter(s)

Amar Kishan, MD - UCLA, Culver City, California